Podcasts about alvotech

Play Episode Listen Later Apr 18, 2024 2:27

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The FDA recently approved a biosimilar of Stelara from Alvotech and Teva, set to launch early next year. Johnson & Johnson reported mixed sales performance for new multiple myeloma drugs, with Tecvayli sales exceeding expectations and Carvykti underperforming. Roche also released survival data for a new lymphoma drug, potentially giving it an edge over a competitor. The US government sued Regeneron for allegedly falsely reporting prices on the blockbuster eye drug Eylea. Other topics covered in the newsletter include drug pricing trends, diversity in clinical trials, and the weight loss drug market.In order to successfully execute health advertising campaigns, marketers need to take a proactive approach by targeting health audience segments online. Actionable insights are provided to maximize the impact of media investment through tips such as implementing a test and learn strategy, scaling results quickly, and asking tough questions to potential health targeting partners. Veeva Crossix is highlighted as a company that implements these tactics to reach consumers throughout the patient journey.Abbott CEO Robert Ford highlighted new and upcoming products during an earnings call, emphasizing the recently approved Triclip valve as a significant opportunity for growth. The FDA issued a warning to Soulaire for selling a device outside of authorized uses. Lilly's obesity drug showed benefits in a sleep disorder study, indicating potential new uses. Johnson & Johnson's $30 billion spending spree on companies like Abiomed, Laminar, and Shockwave Medical may continue. Additionally, Philips entered into a consent decree with the FDA, where the agency will use rare powers to require repairs, replacements, or refunds for recalled respiratory machines.Eli Lilly's weight-loss drug Zepbound has shown effectiveness in treating sleep apnea, leading the company to prepare for a label expansion. Amylyx faced a setback with the failure of its ALS drug Relyvrio, leading to layoffs and market withdrawal. Despite this, the company saw success in treating Wolfram syndrome. Sage Therapeutics also announced the discontinuation of its Parkinson's disease program after disappointing results in phase II trials, shifting focus to Huntington's and Alzheimer's diseases.The medical device industry is increasingly incorporating AI and digital health technologies to improve performance and outcomes. Overall, the medtech sector is evolving rapidly with new products and technologies driving growth and innovation.

#210 – Endurnýjuð heit í hagkvæmnishjónabandi ríkisstjórnarinnar – Flókin staða í hagkerfinu næstu mánuði

Play Episode Listen Later Apr 10, 2024 78:00

Hörður Ægisson og Stefán Einar Stefánsson ræða um skipun nýrrar ríkisstjórnar, hvort líklegt sé að hún nái að leysa þann ágreining sem ríkt hefur, hvaða aðrir möguleikar voru í boði, hvort að VG reyni að sprengja ríkisstjórnina síðar á árinu og hvort að gagnrýni þingmanna Sjálfstæðisflokksins á Svandísi Svavarsdóttur hafi verið innantóm. Þá er rætt um stöðu Alvotech sem hefur valdið óróa á markaði, aukna bindiskyldu bankanna sem mun fela í sér kostnað fyrir viðskiptavini þeirra, brotthvarf aðstoðarseðlabankastjóra, stöðuna í hagkerfinu og margt fleira.

sj stef vg heit svavarsd svand alvotech

#200 – Hér stöndum við og getum ekki annað

Play Episode Listen Later Feb 29, 2024 77:07

Tímamótaþáttur í hlaðvarpi Þjóðmála, þáttur nr. 200. Hörður Ægisson og Stefán Einar Stefánsson fara yfir allt það helsta í viðskiptalífinu, nýtt nafn á sameinað félag Fossa og VÍS, bréf forstjóra Stoða til hluthafa, hversu oft sé hægt að nýta hækkað veiðigjald, samdrátt í hagkerfinu, viðbrögð Seðlabankans, stöðu Alvotech, undarlega baráttu gegn Rapyd, stöðuna í pólitíkinni og margt fleira.

stef sto fossa ekki rapyd alvotech

Salan á Íslandsbanka, endurheimt votlendis og lögleiðing kannabis í Þýskalandi

Play Episode Listen Later Feb 27, 2024 130:00

Ríkisstjórnin hefur ákveðið að selja eftirstandandi hlut ríkisins í Íslandsbanka; rúmlega 40 prósent hlutafjár. Stefnt er að því að allir fái að kaupa – ekki sérvalinn hópur eins og síðast. Þórður Snær Júlíusson, ritstjóri Heimildarinnar, fór yfir söluna. Við ræddum líka um Alvotech sem loksins fær að selja samheitalyf sitt í Bandaríkjunum og fórum yfir stöðu mála í kjaraviðræðunum. Vernd og endurheimt votlendis er eitt af áhersluatriðum í aðgerðaáætlun í loftslagsmálum. Á föstudag fengum við til okkar líffræðing sem sagði frá niðurstöðum rannsóknar sem bendir til þess að smærri votlendissvæði hafi ekki síður þýðingu fyrir lífríkið en stór svæði. Við héldum áfram að fjalla um votlendi og til okkar kom Ágústa Helgadóttir líffræðingur og verkefnastjóri endurheimtar votlendis hjá Landi og skógi til okkar. Arthur Björgvin Bollason var með okkur í dag og fjallaði meðal annars um lögleiðingu kannabisneyslu í Þýskalandi, heimspekinginn Kant og áhuga á Íslandi og því sem íslenskt er á Norðursjávarströndum Þýskalands. Hjarta mítt - Eivör Pálsdóttir. Heimaslóð - Alfreð Washington Þórðarson, Eyjaliðið, Gísli Helgason, Arnþór Helgason, Ási í Bæ. Klau og Klaus - An der Nordseekuste. Tarazina - Setona.

kant sn arn bandar landi klau eiv helgason glei helgad hjarta salan alvotech stefnt bollason

#192 – Verðbólgan kólnar og gul viðvörun á vinnumarkaði – Er ástæða til að stofna þjóðarsjóð?

Not So Different: a Podcast from The Center for Biosimilars

Play Episode Listen Later Jan 31, 2024 78:59

Hörður Ægisson og Stefán Einar Stefánsson ræða um hjaðnandi verðbólgu og útlitið framundan, hvort að von sá á vaxtalækkun, kjaraviðræður sem nú eru í frosti, ummæli Vilhjálms Birgissonar í nýlegu viðtali í Spursmálum, hvort að rétt sé að stofna þjóðarsjóð eða ekki, andstöðu Landverndar við framförum, um stöðu Alvotech og Marel og margt fleira.

stef vilhj marel landverndar alvotech stofna

Highlights from ACG 2023

Meeting Mic

Play Episode Listen Later Nov 7, 2023 25:02

In this episode of Meeting Mic, we bring you Healio's top headlines from ACG 2023. Paul Feuerstadt, MD, FACG, AGAF, discusses data that link health-related quality of life and microbiome composition among patients with recurrent Clostridioides difficile infection. :38 Edward V. Loftus Jr., MD, FACG, discusses results from the INSPIRE trial for ulcerative colitis. 7:52 Jan Wehkamp, MD, PhD, discusses results from the QUASAR study, in which Tremfya outperformed placebo in clinical response patients with ulcerative colitis. 12:08 Paul Feuerstadt also discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. 15:32 Thomas F. Imperiale, MD, discusses the results of the BLUE-C study, which evaluated the clinical performance of Cologuard, a next-generation, multitarget stool DNA test. 21:08 Read the full coverage here: https://www.healio.com/news/gastroenterology/20231023/video-rebyota-not-only-shuts-down-recurrence-also-affects-quality-of-life-in-c-diff https://www.healio.com/news/gastroenterology/20231025/video-risankizumab-a-great-option-for-patients-induces-clinical-remission-in-uc https://www.healio.com/news/gastroenterology/20231024/video-more-than-75-of-uc-patients-achieve-clinical-response-at-24-weeks-with-tremfya https://www.healio.com/news/gastroenterology/20231025/video-future-is-now-here-for-recurrent-c-difficile-thanks-to-live-biotherapeutics https://www.healio.com/news/gastroenterology/20231025/sensitivity-of-nextgeneration-cologuard-in-precancer-detection-numerically-exceeded-fit Disclosures: Feuerstadt reports financial relationships with Ferring Pharmaceuticals, Regeneron Pharmaceuticals, Seres Therapeutics and Takeda Pharmaceuticals. Imperiale reports grant and research support from Exact Sciences. Loftus reports financial relationships with AbbVie, Alvotech, Amgen, Arena, Avalo Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Exact Sciences, Fresenius Kabi, Genentech, Gilead, GlaxoSmithKline, Gossamer Bio, Iota Biosciences, Iterative Scopes, Janssen, KSL Diagnostics, Lilly, Morphic, Ono Pharma, Pfizer, Protagonist, Receptos, Robarts Clinical Trials, Scipher Medicine, Sun Pharma, Surrozen, Takeda, Theravance and UCB. Wehkamp reports no relevant financial disclosures.

phd dna md fda inspire arena pfizer protagonists gilead janssen ucb genentech amgen glaxosmithkline abbvie loftus bristol myers squibb takeda quasar boehringer ingelheim acg imperiale celgene regeneron pharmaceuticals exact sciences morphic agaf sun pharma wehkamp healio seres therapeutics alvotech receptos

S6 Ep19: Biosimilar Business Roundup for October 2023—Podcast Edition

Play Episode Listen Later Nov 5, 2023 5:13

FDA Approves First Subcutaneous Infliximab Product Abrilada Approved as Second Interchangeable Humira Biosimilar Eye on Pharma: New GI Data and Byooviz Interchangeability Propel Biosimilars Into the Future Biosimilars Check-In: BI Launches Unbranded Adalimumab; New Omalizumab Deal; CRL for Insulin Aspart Eye on Pharma: Another CRL for Alvotech; Cimerli's Growing Market Share; BBCIC Awarded Grant Samsung Bioepis Presents Positive Phase 3 Data on Aflibercept Candidate AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry

data podcast edition crl biosimilar alvotech

Pharma and Biotech Daily: From Cell Therapies to Gene Editing - Insights and Challenges in the Industry

Play Episode Listen Later Oct 13, 2023 4:09

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Bayer has recently opened a new plant in California to produce cell therapies, specifically a Parkinson's disease treatment being tested by its subsidiary Bluerock. This is a significant step forward in the field of cell therapy development.Meanwhile, Sana, another cell therapy developer, is implementing cost-saving measures, including layoffs and delaying certain research projects. These actions are aimed at ensuring the company's financial stability.In the world of biotech, Crispr gene editing technology is gaining increasing importance. Many companies in this field are led by former students of the pioneering scientists in the Crispr field. This shows the significant impact and potential of this technology.After a slow summer, there has been an uptick in biotech M&A activity. One notable acquisition is that of Orchard Therapeutics. This indicates the growing interest and investment in the biotech industry.In regulatory news, Pepgen has received clearance from the FDA to begin a study of its muscular dystrophy drug. This is an important milestone for the company, and we can expect to see the first results of this study next year.On the other hand, Alnylam has faced a setback as the FDA denied expanded approval for its RNA drug for a rare heart condition. This decision has set back the company's plans, highlighting the challenges faced by pharmaceutical companies in gaining regulatory approval for their products.Moving on to other news, Alvotech, a biopharmaceutical company, has received another rejection from the FDA for its biosimilar of Stelara. The FDA cited "deficiencies" at Alvotech's manufacturing plant as the reason for the rejection. This marks the fourth FDA rejection for Alvotech since last year.In a recent acquisition, Biogen has announced layoffs at Reata Pharmaceuticals, which it acquired for $7 billion. These layoffs will impact approximately one-third of Reata's workforce.In regulatory news, the European Commission has ordered Illumina to divest its subsidiary Grail. This decision comes after years of regulatory challenges and investigations.In clinical trial updates, Eli Lilly's mirikizumab has shown promising results in a Phase III trial for Crohn's disease. Over 54% of patients treated with mirikizumab achieved clinical remission at 52 weeks. Eli Lilly plans to submit a marketing application for mirikizumab in Crohn's disease to the FDA in 2024.Overall, these developments highlight the challenges faced by pharmaceutical companies in gaining regulatory approval for their products and the impact of acquisitions on workforce restructuring.The recent rejection by the FDA of a label expansion for Alnylam Pharmaceuticals' drug Onpattro to treat a rare heart condition has caused disappointment for the company. However, CEO Yvonne Greenstreet has outlined the company's future plans.This rejection sheds light on the challenges faced by drugmakers in gaining approval for their treatments. There is a delicate balance between patients and drugmakers wanting more liberal approval processes, while the medical community aims to ensure that drugs provide significant benefits compared to the risks.The FDA has been working towards bridging this gap through programs like Accelerating Rare Disease Cures (ARC). ARC aims to provide education campaigns and resources for developers to ensure all stakeholders are aligned.Alnylam's rejection serves as a reminder that surprises can still arise in the drug development and regulatory arenas. It also highlights the need for continuous innovation and adaptation in this field.Looking ahead, gene editing technology, particularly CRISPR-based therapies, holds great promise and could soon receive US approval. Many startups and scientists are actively working on advancements in this gene editing revolution.In summary, Alnylam's disap

Pharma and Biotech Daily: Industry Updates and Insights for the Informed Professional

Play Episode Listen Later Sep 21, 2023 3:48

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Today's episode covers a range of updates in the industry.First, we turn our attention to the commercial hurdles facing RSV vaccines. Public health officials and drugmakers are working to raise awareness of RSV among older adults at risk. They are also encouraging them to get an additional respiratory shot alongside those for COVID-19 and flu. This rollout poses a test for the industry.In a recent House hearing, the pharmacy benefit manager lobby PCMA and drugmaker lobby PhRMA traded blame over problems in the prescription supply chain. They discussed the high costs of drugs and the role that PBMs play in driving up prices. This ongoing debate highlights the challenges within the industry.Moving on, Alvotech has received a new FDA review for its biosimilar of Humira. The regulator had previously rejected Alvotech's copycat drug due to manufacturing issues with a plant in Europe. This new review brings hope for Alvotech's biosimilar.Novartis has canceled its partnership with Beigene as its cancer drug gains EU approval. This decision leaves Novartis without a PD-1 inhibitor, marking a significant development for the company.Orchard is nearing an FDA decision on its rare disease gene therapy, Libmeldy. Three years after gaining European approval, Libmeldy is now under review in the US. This therapy has the potential to make a difference in the lives of patients.Shifting gears, an FDA panel has backed Alnylam's drug Onpattro for cardiomyopathy of ATTR amyloidosis, despite doubts over its benefit. This endorsement provides support for this drug's use in treating this condition.We also have various resources for further reading and upcoming events available. Check out Biopharma Dive and its publications for more information.In another news story, Roche's Genentech has partnered with PeptiDream to develop targeted radioisotopes for certain cancers. This collaboration expands their efforts in radiopharmaceuticals and shows promise for future treatments.Taysha has made the decision to drop its lead gene therapy, TSHA-120, following feedback from the FDA. The agency proposed additional studies that Taysha determined would be too challenging to pursue. Additionally, Taysha's partner, Astellas, has declined to pick up an option for the therapy. These developments mark a setback for Taysha.The FDA has also rejected ARS Pharmaceuticals' Neffy as a nasal spray for allergic reactions. Despite receiving backing from the Pulmonary-Allergy Drugs Advisory Committee, this rejection is a setback for ARS. The nasal spray was seen as an alternative to the EpiPen for severe allergic reactions.In other news, Genentech and PeptiDream have signed a potential $1 billion deal for the development of macrocyclic peptide-radioisotope drug conjugates. This partnership has the potential to advance cancer treatments and improve patient outcomes.Recode Therapeutics has raised $260 million in a series B financing round to advance its mRNA therapies. This funding will support further development in this promising field.The clearance of the Amgen-Horizon merger has been seen as a setback to the FTC's antitrust enforcement plans. The consent agreement between Amgen, Horizon Therapeutics, and the FTC could have significant implications for future merger and acquisition challenges.Lastly, Verisim Life has released an ebook on how artificial intelligence can transform R&D with early-stage translational insights in model-informed drug development. This resource provides valuable information on the potential of AI in drug development.That's all for today's episode. Thank you for tuning in to Pharma and Biotech Daily. Stay informed and stay ahead in the industry.

Pharma and Biotech Daily: Mergers, Regulations, and Breakthroughs in the Industry

Podcast með Sölva Tryggva

Play Episode Listen Later Sep 4, 2023 4:14

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. The Federal Trade Commission (FTC) has allowed Amgen's $28 billion acquisition of Horizon to proceed, with conditions. This settlement may ease concerns about regulatory hurdles for future deals in the industry. However, FDA documents suggest that Sage's depression drug, zurzuvae, may face challenges in obtaining broad approval due to concerns about side effects. On a positive note, Roche has claimed success in a study for its targeted lung cancer drug, Alecensa, with unprecedented results. This could make Alecensa the first treatment specifically available after surgery for ALK-positive lung tumors.In terms of investment, Julie Yoo from venture capital firm Andreessen Horowitz believes that the healthcare industry is at an inflection point and compared it to the internet era of 1999. Biotech mergers and acquisitions (M&A) activity is also picking up again, with Amgen's acquisition of Horizon set to become the largest industry deal since AstraZeneca's buyout of Alexion. Drug pricing in the US is also a trending topic, with launch prices steadily rising in certain therapeutic areas like cancer.Moving on to policy news, the Biden administration has proposed new nursing home staffing minimums to improve the quality of care in these facilities. Walgreens CEO Roz Brewer is stepping down and will be replaced by an executive with "deep healthcare experience." Amir Dan Rubin, CEO of One Medical, is also resigning from his position. The Office of the National Coordinator for Health Information Technology has chosen the Sequoia Project to oversee the Trusted Exchange Framework and Common Agreement (TEFCA) once again.In other updates, Roz Brewer's sudden departure from Walgreens has left many wondering about the reason behind it. Psycheceutical is developing a topical delivery technology for ketamine, which could have broader implications for other drugs. Ketamine has shown promise in treating mental health conditions such as treatment-resistant depression. J&J's Spravato, an FDA-approved drug for treatment-resistant depression, is administered nasally, but clinicians believe that intravenous ketamine is more effective. Psycheceutical aims to explore the potential relief provided by applying ketamine topically on the back of the neck.The rare disease market has seen significant growth in recent years, with pharmaceutical companies exploring treatments for these conditions. Ketamine's effectiveness in battling mental health conditions is being recognized, shifting its perception from a party drug to a potential therapeutic option. The text also mentions upcoming events and recent articles on various topics.In regulatory news, the FTC has given clearance for Amgen's acquisition of Horizon Therapeutics, subject to certain restrictions. Alvotech has resubmitted a Biologics License Application (BLA) to the FDA seeking an interchangeable designation for its biosimilar of Humira. Lawmakers have called on Lilly, Novo Nordisk, and Sanofi to provide details on their insulin assistance programs. Alkermes has settled a patent lawsuit with Teva over the generic version of Vivitrol. Biontech and DualityBio are moving their antibody-drug conjugate (ADC) into Phase III trials for HER2-low breast cancer.Lastly, Bayer has reported positive early data for a Parkinson's cell therapy treatment it acquired in 2019. Epigenic, a Chinese startup, has raised funds to use CRISPR tools to edit the epigenome and alter gene expression without changing DNA. Catalent, a contract development and manufacturing organization (CDMO), is expanding its board and setting up a committee to review its business and capital allocation priorities. Several biotech companies have made advancements in constructing small-molecule drugs to target RNA, revolutionizing the industry.These developments highlight significant activities in the p

Róbert Wessman (brot af því besta)

Play Episode Listen Later Sep 1, 2023 24:29

Róbert Wessman er stofnandi Alvotech og Alvogen. Í þættinum ræða Sölvi og Róbert um feril Róberts, hjólreiðar, alvarlegt slys sem Róbert varð fyrir, eftirmálana af því, Covid tímabilið og margt margt fleira. Þátturinn er í boði; Fitness Sport - https://www.fitnesssport.is/ Heilsubarinn - https://www.heilsubarinn.is/ Ozon - https://www.ozonehf.is/ Narfeyrarstofa - https://narfeyrarstofa.is/ Nýja vínbúðin - https://nyjavinbudin.is/

covid-19 brot besta ozon wessman alvotech alvogen

Fornbréf veita innsýn í horfinn heim

Play Episode Listen Later Jul 4, 2023

Þrír stjórnendur hafa hætt störfum í Íslandsbanka eftir að í ljós kom hvernig staðið var að sölu bankans á bréfum í honum sjálfum. Þórður Snær Júlíusson, ritstjóri Heimildarinnar, fór yfir stöðuna í málefnum Íslandsbanka. Hann ræddi líka um samdrátt í kaupmætti, fjármagnstekjur og Alvotech. Þýski öfgaflokkurinn AfD mælist enn með mikinn meðbyr í skoðanakönnunum og mældist á dögunum með meira fylgi en stjórnarflokkur jafnaðarmanna SPD. Arthúr Björgvin Bollason var á línunni frá Berlín og sagði frá umdeildu viðtali sem vikuritið Stern birti við annan formanna flokksins, Alice Weidel. Í síðustu viku var greint frá því að Stofnun Árna Magnússonar í íslenskum fræðum hefði móttekið tvö hundruð milljónir króna styrk frá danska sjóðnum A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond. Styrkurinn er ætlaður til að gera stafrænan gagnagrunn um fornbréf og skjöl úr safni ÁRna Magnússonar. Þórunn Sigurðardóttir rannsóknarprófessor fer fyrir þessu verkefni og var gestur Morgunvaktarinnar. Tónlist: The Boxer - Simon and Garfunkel Cecilia - Simon and Garfunkel Ein Sonderzug nach Pankow - Udo Lindenberg Skýjaglópur - Júníus Meyvant Umsjón: Vera Illugadóttir og Þórunn Elísabet Bogadóttir.

bj stern inns afd spd fond berl sn magn heim hann sigur alice weidel arth stofnun vera illugad alvotech bollason

Fornbréf veita innsýn í horfinn heim

Play Episode Listen Later Jul 4, 2023 130:00

Þrír stjórnendur hafa hætt störfum í Íslandsbanka eftir að í ljós kom hvernig staðið var að sölu bankans á bréfum í honum sjálfum. Þórður Snær Júlíusson, ritstjóri Heimildarinnar, fór yfir stöðuna í málefnum Íslandsbanka. Hann ræddi líka um samdrátt í kaupmætti, fjármagnstekjur og Alvotech. Þýski öfgaflokkurinn AfD mælist enn með mikinn meðbyr í skoðanakönnunum og mældist á dögunum með meira fylgi en stjórnarflokkur jafnaðarmanna SPD. Arthúr Björgvin Bollason var á línunni frá Berlín og sagði frá umdeildu viðtali sem vikuritið Stern birti við annan formanna flokksins, Alice Weidel. Í síðustu viku var greint frá því að Stofnun Árna Magnússonar í íslenskum fræðum hefði móttekið tvö hundruð milljónir króna styrk frá danska sjóðnum A.P. Møller og Hustru Chastine Mc-Kinney Møllers Fond. Styrkurinn er ætlaður til að gera stafrænan gagnagrunn um fornbréf og skjöl úr safni ÁRna Magnússonar. Þórunn Sigurðardóttir rannsóknarprófessor fer fyrir þessu verkefni og var gestur Morgunvaktarinnar. Tónlist: The Boxer - Simon and Garfunkel Cecilia - Simon and Garfunkel Ein Sonderzug nach Pankow - Udo Lindenberg Skýjaglópur - Júníus Meyvant Umsjón: Vera Illugadóttir og Þórunn Elísabet Bogadóttir.

bj stern inns afd spd fond berl sn magn heim hann sigur alice weidel arth stofnun vera illugad alvotech bollason

#125 – Andvökunætur Alvotech – Bjagaðar hugmyndir Katrínar um arðgreiðslur

Play Episode Listen Later Apr 19, 2023 68:09

Hörður Ægisson og Stefán Einar Stefánsson ræða um þær áskoranir sem Alvotech stendur frammi fyrir, hóflega væntingastjórnun til vaxtafyrirtækja og hvaða afleiðingar rekstur félagsins getur haft á íslenskt efnahagslíf. Þá er rætt um misheppnaða tilraun forsætisráðherra til að tengja saman arðgreiðslur og verðbólgu, aðför matvælaráðherra að sjávarútvegi, stöðuna á samruna VÍS og Fossa og undarlegan skort á vilja yfirvalda til að hækka lánshæfismat landsins. Það er komið víða við í þætti dagsins.

stef slurs katr fossa grei hugmyndir alvotech

Efnahagur og samfélag, Berlínarspjall og Baugur Bjólfs

Play Episode Listen Later Apr 18, 2023

Þórður Snær Júlíusson ritstjóri Heimildarinnar, fór yfir það helsta í efnahag og samfélagi þjóðarinnar. Svo sem fjármál sveitarfélaganna og ákvörðun bandaríska lyfjaeftirlitsins sem hefur sett rautt strik í reikning Alvotech. Arthúr Björgvin Bollason fjallaði um lokun kjarnorkuvera í Þýskalandi og hugmyndir um lögleiðingu kannabisefna í Berlínarspjalli. Ástríður Birna Árnadóttir og Stefanía Helga Pálmarsdóttir aðalhönnuðir útsýnispalls á fjalli Seyðfirðinga, Bjólfi, sögðu frá útsýnispallinum sem hefur hlotið heitið Baugur Bjólfs en framkvæmdin hefur fengið styrk úr Framkvæmdasjóði ferðamála. Tónlist: Vorvindar glaðir - Andrea Gylfadóttir, Vaki, vaki vinur minn - Erla Þorsteinsdóttir, That Ole Devil Called Love - Tríó Sigurðar Flosasonar, With your eyes closed - Fabúla (Margrét Kristín Sigurðardóttir). Umsjón: Björn Þór Sigbjörnsson og Guðrún Hálfdánardóttir.

bj gu fab berl sn krist sigur svo margr arth sey sam f sigbj umsj erla birna framkv alvotech bollason andrea gylfad

Efnahagur og samfélag, Berlínarspjall og Baugur Bjólfs

Play Episode Listen Later Apr 18, 2023 130:00

Þórður Snær Júlíusson ritstjóri Heimildarinnar, fór yfir það helsta í efnahag og samfélagi þjóðarinnar. Svo sem fjármál sveitarfélaganna og ákvörðun bandaríska lyfjaeftirlitsins sem hefur sett rautt strik í reikning Alvotech. Arthúr Björgvin Bollason fjallaði um lokun kjarnorkuvera í Þýskalandi og hugmyndir um lögleiðingu kannabisefna í Berlínarspjalli. Ástríður Birna Árnadóttir og Stefanía Helga Pálmarsdóttir aðalhönnuðir útsýnispalls á fjalli Seyðfirðinga, Bjólfi, sögðu frá útsýnispallinum sem hefur hlotið heitið Baugur Bjólfs en framkvæmdin hefur fengið styrk úr Framkvæmdasjóði ferðamála. Tónlist: Vorvindar glaðir - Andrea Gylfadóttir, Vaki, vaki vinur minn - Erla Þorsteinsdóttir, That Ole Devil Called Love - Tríó Sigurðar Flosasonar, With your eyes closed - Fabúla (Margrét Kristín Sigurðardóttir). Umsjón: Björn Þór Sigbjörnsson og Guðrún Hálfdánardóttir.

bj gu fab berl sn krist sigur svo margr arth sey sam f sigbj umsj erla birna framkv alvotech bollason andrea gylfad

Verðbólga, Lilja í Berlín og Borgarskjalasafn

Play Episode Listen Later Mar 7, 2023 130:00

Þórður Snær Júlíusson fór yfir áhrif verðbólgunnar, sem nú mælist rúmlega tíu prósent, á landsmenn. Vaxtahækkanir, til að mæta verðbólgunni, bitna harkalega á fólki, einkum fólki með óverðtryggð fasteignalán á breytilegum vöxtum. Hann talaði líka um fyrirtækið Alvotech sem rekið var með 70 milljarða króna halla á síðasta ári en vonast er eftir hagnaði á þessu ári. Í Berlínarspjalli ræddi Arthúr Björgvin Bollason við Lilju Alfreðsdóttur menningar- og viðskiptaráðherra. Hún er stödd í Berlín m.a. til að hitta þýska starfssystur og sækja heilmikla ferðakaupstefnu sem þar er haldin. Leggja á Borgarskjalasafn niður. Tillaga borgarstjóra þess efnis verður rædd og tekin til atkvæðagreiðslu á borgarstjórnarfundi í dag. Svanhildi Bogadóttur borgarskjalaverði líst illa á áformin. Hún ræddi þau og starfsemi safnsins. Tónlist: Ég er glataður án þín - Lúdó og Stefán, Chan, chan - Compay Segundo, Svanasöngur á heiði - Pétur Á. Jónsson. Umsjón: Björn Þór Sigbjörnsson.

bj chan berl stef sn hann lilja arth sigbj umsj compay segundo alvotech lilju alfre bollason

Verðbólga, Lilja í Berlín og Borgarskjalasafn

Play Episode Listen Later Mar 7, 2023

Þórður Snær Júlíusson fór yfir áhrif verðbólgunnar, sem nú mælist rúmlega tíu prósent, á landsmenn. Vaxtahækkanir, til að mæta verðbólgunni, bitna harkalega á fólki, einkum fólki með óverðtryggð fasteignalán á breytilegum vöxtum. Hann talaði líka um fyrirtækið Alvotech sem rekið var með 70 milljarða króna halla á síðasta ári en vonast er eftir hagnaði á þessu ári. Í Berlínarspjalli ræddi Arthúr Björgvin Bollason við Lilju Alfreðsdóttur menningar- og viðskiptaráðherra. Hún er stödd í Berlín m.a. til að hitta þýska starfssystur og sækja heilmikla ferðakaupstefnu sem þar er haldin. Leggja á Borgarskjalasafn niður. Tillaga borgarstjóra þess efnis verður rædd og tekin til atkvæðagreiðslu á borgarstjórnarfundi í dag. Svanhildi Bogadóttur borgarskjalaverði líst illa á áformin. Hún ræddi þau og starfsemi safnsins. Tónlist: Ég er glataður án þín - Lúdó og Stefán, Chan, chan - Compay Segundo, Svanasöngur á heiði - Pétur Á. Jónsson. Umsjón: Björn Þór Sigbjörnsson.

bj chan berl stef sn hann lilja arth sigbj umsj compay segundo alvotech lilju alfre bollason

#110 – Ríkissáttasemjari ýtir á rauða hnappinn – Meðalgóður dansari stígur út á sviðið og skyggir á ballerínuna

Empowered Patient Podcast

Play Episode Listen Later Jan 26, 2023 60:38

Hörður Ægisson og Stefán Einar Stefánsson fjalla um nýjustu vendingar í kjaramálum eftir að ríkissáttasemjari lagði fram miðlunartillögu sem knýr félagsmenn í Eflingu til að kjósa um þann kjarasamning sem lagður hefur verið fram og samþykktur af öðrum félögum. Rætt er um hvort það sé ábyrg ákvörðun eða ótímabær. Þá er rætt um stöðu ÍL sjóðs, hvort að fyrrverandi umboðsmaður Alþingis hafi eitthvað raunverulegt fram að færa um sölu ríkisins í Íslandsbanka, um uppkaup á gjaldeyrismarkaði og hversu spenntir íslenskir fjárfestar eru fyrir Alvotech.

kiss stef baller nuna alvotech eflingu

Developing Biosimilars to Drive Down Costs and Incentivize Innovation with Ming Li Alvotech

Play Episode Listen Later Nov 8, 2022 17:59

Ming Li is the Chief Strategy Officer at Alvotech, a biosimilar-only company developing biosimilar drugs to provide lower-cost alternatives in the global marketplace. Biosimilars are analogous to generic medicines, but these drugs are complex molecules developed and produced out of living systems, requiring sophisticated manufacturing processes and often litigation. The bulk of success in biologics has been in oncology, immunology, gastrointestinal diseases, asthma, and osteoporosis. Ming explains, "Biosimilars are somewhat analogous to generic medicines in that they are slightly less expensive to develop than it would be to develop a new molecule. They can be offered at a lower price to patients and healthcare systems. So, we are focusing on developing these more affordable biosimilars. We really think that there's an opportunity here because as biologics have become the standard of care across many different areas, they've also become a large portion of the costs when you look at pharma more broadly." "In the US, as an example, I think it's almost 45 cents of every dollar spent on pharma is on a biologic. It's complex to develop biosimilars, and they call them similar because they're not exactly the same in the sense that these molecules are so complex you cannot create the exact same molecule. You have to control your process and develop your process and your product and your molecule within certain parameters that are accepted from regulatory agencies. We do aim to navigate those globally, navigate the regulatory environments globally and launch these products in almost every market in the world. That's our aim." #Alvotech #Biosimilars #Biologics #Immunology #Oncology #GenericDrugs #Iceland alvotech.com Download the transcript here

innovation drive developing costs chief strategy officer ming incentivize biosimilars alvotech

Developing Biosimilars to Drive Down Costs and Incentivize Innovation with Ming Li Alvotech TRANSCRIPT

Empowered Patient Podcast

Play Episode Listen Later Nov 8, 2022

Ming Li is the Chief Strategy Officer at Alvotech, a biosimilar-only company developing biosimilar drugs to provide lower-cost alternatives in the global marketplace. Biosimilars are analogous to generic medicines, but these drugs are complex molecules developed and produced out of living systems, requiring sophisticated manufacturing processes and often litigation. The bulk of success in biologics has been in oncology, immunology, gastrointestinal diseases, asthma, and osteoporosis. Ming explains, "Biosimilars are somewhat analogous to generic medicines in that they are slightly less expensive to develop than it would be to develop a new molecule. They can be offered at a lower price to patients and healthcare systems. So, we are focusing on developing these more affordable biosimilars. We really think that there's an opportunity here because as biologics have become the standard of care across many different areas, they've also become a large portion of the costs when you look at pharma more broadly." "In the US, as an example, I think it's almost 45 cents of every dollar spent on pharma is on a biologic. It's complex to develop biosimilars, and they call them similar because they're not exactly the same in the sense that these molecules are so complex you cannot create the exact same molecule. You have to control your process and develop your process and your product and your molecule within certain parameters that are accepted from regulatory agencies. We do aim to navigate those globally, navigate the regulatory environments globally and launch these products in almost every market in the world. That's our aim." #Alvotech #Biosimilars #Biologics #Immunology #Oncology #GenericDrugs #Iceland alvotech.com Listen to the podcast here

innovation drive developing costs chief strategy officer ming incentivize biosimilars alvotech

Englandsdrottning, útlendingar, ferðamenn og íslenskan

Play Episode Listen Later Sep 9, 2022 130:00

Ingibjörg Rósa Björnsdóttir blaðamaður í Edinborg sagði frá viðbrögðum Skota og annarra Breta við dauða Elísabetar Englandsdrottningar en Elísabet lést síðdegis í gær í kastala konungsfjölskyldunnar í Balmoral í Skotlandi. Um fjórðungur fólks á vinnumarkaði eru útlendingar og allt stefnir í að hlutfallið eigi bara eftir að hækka. Eitt þeirra fyrirtækja sem hefur leitað eftir sérfræðingum erlendis frá er líftæknifyrirtækið Alvotech. Birna Björnsdóttir, sem heldur utan um komu þeirra til Íslands, fór yfir það hvernig staðið er að móttöku erlendra starfsmanna hjá fyrirtækinu. Tæplega helmingur starfsmanna Alvotech eru útlendingar og eru Indverjar fjölmennastir. Nýjar spár um umferð um Keflavíkurflugvöll eru bjartsýnari en áður. Það er þó töluverð óvissa í loftinu, meðal annars vegna ástands mála í Bretlandi, þaðan sem margir ferðamenn til Íslands koma. Kristján Sigurjónsson, ritstjóri Túrista, fór yfir horfur í ferðaþjónustu sem og vinsældir ferðalaga til Tenerife og skíðaferðir í Alpana. Ármann Jakobsson prófessor við Háskóla Íslands velti vinsældum íslenskunnar fyrir sér í grein á Vísi í vikunni. Þar kemur fram að rannsóknir sýni að íslenska sé orðin óvinsæl námsgrein á flestum skólastigum og í kjölfarið er spurt hvort óvinsældirnar nái til tungumálsins sjálfs. Ármann telur að það eigi að beita refsingum þegar kemur að brotum á lögum er varða íslenskuna.

bj tenerife kristj jakobsson breta eitt sigurj ingibj keflav bretlandi alpana alvotech

Englandsdrottning, útlendingar, ferðamenn og íslenskan

Play Episode Listen Later Sep 9, 2022

Ingibjörg Rósa Björnsdóttir blaðamaður í Edinborg sagði frá viðbrögðum Skota og annarra Breta við dauða Elísabetar Englandsdrottningar en Elísabet lést síðdegis í gær í kastala konungsfjölskyldunnar í Balmoral í Skotlandi. Um fjórðungur fólks á vinnumarkaði eru útlendingar og allt stefnir í að hlutfallið eigi bara eftir að hækka. Eitt þeirra fyrirtækja sem hefur leitað eftir sérfræðingum erlendis frá er líftæknifyrirtækið Alvotech. Birna Björnsdóttir, sem heldur utan um komu þeirra til Íslands, fór yfir það hvernig staðið er að móttöku erlendra starfsmanna hjá fyrirtækinu. Tæplega helmingur starfsmanna Alvotech eru útlendingar og eru Indverjar fjölmennastir. Nýjar spár um umferð um Keflavíkurflugvöll eru bjartsýnari en áður. Það er þó töluverð óvissa í loftinu, meðal annars vegna ástands mála í Bretlandi, þaðan sem margir ferðamenn til Íslands koma. Kristján Sigurjónsson, ritstjóri Túrista, fór yfir horfur í ferðaþjónustu sem og vinsældir ferðalaga til Tenerife og skíðaferðir í Alpana. Ármann Jakobsson prófessor við Háskóla Íslands velti vinsældum íslenskunnar fyrir sér í grein á Vísi í vikunni. Þar kemur fram að rannsóknir sýni að íslenska sé orðin óvinsæl námsgrein á flestum skólastigum og í kjölfarið er spurt hvort óvinsældirnar nái til tungumálsins sjálfs. Ármann telur að það eigi að beita refsingum þegar kemur að brotum á lögum er varða íslenskuna.

bj tenerife kristj jakobsson breta eitt sigurj ingibj keflav bretlandi alpana alvotech

Englandsdrottning, útlendingar, ferðamenn og íslenskan